Regulatory Background

Starting in 2029, federal rules aim to close a loophole that protects the pricing of drugs switching from intravenous (IV) infusion to subcutaneous (SC) injection. This is part of a broader federal effort to reduce Medicare costs and comes amid increasing pressure to address drug price inflation. The rule is being introduced at a time when major cancer drugs are actively developing subcutaneous formulations.

Key Drugs Affected

Keytruda and Opdivo are currently administered via IV infusion, but subcutaneous formulations are in clinical trials. Subcutaneous formulations are expected to improve patient compliance by increasing ease of administration. However, if the new formulations do not receive the same price protection, Medicare may apply lower pricing.

Impact on Pricing and Patient Access

Without price protection, Medicare may renegotiate drug prices or directly reduce reimbursement rates. This could put direct pressure on pharmaceutical companies' revenues, while potentially reducing costs for patients. However, price reductions could also negatively impact the return on investment for new drug development.

Broader Industry Implications

The regulation could apply to all biologics switching from IV infusion to subcutaneous injection, potentially triggering a re-evaluation of pricing strategies across the industry. Similar price protection regulations have been discussed in Europe, and this could serve as a precedent for global pricing policy changes. Companies will need to carefully adjust the timing of subcutaneous formulation launches and pricing strategies.